USPTO serial 85440797
TESIVEE
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- HWANG, JOHN C B
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with TESIVEE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
HAMILTON, BM
DUBLIN, IE
Valeant International (Barbados) SRL
Christ Church, BB
Other trademarks owned by Valeant International (Barbados) SRL
Valeant International (Barbados) SRL
Christ Church, BB
Other trademarks owned by Valeant International (Barbados) SRL
VALEANT PHARMACEUTICALS LUXEMBOURG S.À.R.L
LUXEMBOURG CITY, LU
Other trademarks owned by VALEANT PHARMACEUTICALS LUXEMBOURG S.À.R.L
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Christopher L. Graff
Christopher L. Graff Pirkey Barber PLLC60600 Congress Avenue, Suite 2120Austin, TX 78701Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders ; Pharmaceutical preparations and substances for the treatment of infectious diseases; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations and substances for use in chemotherapy; Pharmaceutical preparations and substances for use in urology; Pharmaceutical preparations and substances for the prevention, treatment and alleviation of stress; pharmaceutical preparations and substances for the prevention, treatment and alleviation of diabetes; pharmaceutical preparations and substances for controlling insulin levels; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension; pharmaceutical preparations and substances for the prevention, treatment and alleviation of angina; pharmaceutical preparations and substances for the cessation of smoking; pharmaceutical preparations and substances for the prevention and treatment of sexually transmitted diseases; pharmaceutical preparations and substances for the prevention and treatment of herpes; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the central nervous system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of depression; anti-depressants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of sleep disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of anxiety; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the cardio-vascular system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of acute myocardial infarctions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of symptomatic congestive heart failure; pharmaceutical preparations and substances for the prevention, treatment and alleviation of asymptomatic left ventricular dysfunction; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain and inflammation, namely, anti-inflammatories and pain relief medication; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; Pharmaceutical preparations and substances for the treatment of fungal infections, onychomycosis, tinea infections, and similar diseases of the skin and nails; Pharmaceutical preparations and substances for use in dermatological conditions | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by VALEANT INTERNATIONAL BERMUDA
- Other trademarks owned by VALEANT HOLDINGS IRELAND
- Other trademarks owned by Valeant International (Barbados) SRL
- Other trademarks owned by Valeant International (Barbados) SRL
- Other trademarks owned by VALEANT PHARMACEUTICALS LUXEMBOURG S.À.R.L
- Other trademarks in Class 005
- Similar marks named TESIVEE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 16, 2025 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Jan 11, 2017 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Dec 7, 2016 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Dec 5, 2016 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 5, 2016 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| May 21, 2016 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 20, 2016 | EX4G | SOU EXTENSION 4 GRANTED | — |
| May 3, 2016 | NREV | NOTICE OF REVIVAL - E-MAILED | — |
| May 2, 2016 | TPEX | SOU EXTENSION RECEIVED WITH TEAS PETITION | — |
| May 2, 2016 | PETG | PETITION TO REVIVE-GRANTED | — |
| May 2, 2016 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| Apr 29, 2016 | EXT4 | SOU EXTENSION 4 FILED | — |
| Mar 3, 2016 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 21, 2015 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED | — |
| Nov 20, 2015 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Oct 30, 2015 | NREV | NOTICE OF REVIVAL - MAILED | — |
| Oct 30, 2015 | TPEX | SOU EXTENSION RECEIVED WITH TEAS PETITION | — |
| Oct 30, 2015 | PETG | PETITION TO REVIVE-GRANTED | — |
| Oct 30, 2015 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| Oct 29, 2015 | EXT3 | SOU EXTENSION 3 FILED | — |
| Apr 10, 2015 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED | — |
| Apr 8, 2015 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Apr 8, 2015 | EXT2 | SOU EXTENSION 2 FILED | — |
| Apr 8, 2015 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 21, 2015 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Nov 19, 2014 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED | — |
| Nov 18, 2014 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Nov 17, 2014 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Oct 23, 2014 | EXT1 | SOU EXTENSION 1 FILED | — |
| Oct 23, 2014 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 29, 2014 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Mar 4, 2014 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 12, 2014 | NPUB | NOTICE OF PUBLICATION | — |
| Jan 30, 2014 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jan 29, 2014 | CNEA | EXAMINERS AMENDMENT MAILED | — |
| Jan 28, 2014 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 28, 2014 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 28, 2014 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 27, 2014 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 27, 2014 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 27, 2014 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jan 22, 2014 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 22, 2014 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 25, 2013 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jul 25, 2013 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jul 25, 2013 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jul 23, 2013 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 23, 2013 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 17, 2013 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Jan 22, 2013 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Jan 22, 2013 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Jan 22, 2013 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Jan 22, 2013 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Jan 9, 2013 | ALIE | ASSIGNED TO LIE | — |
| Aug 15, 2012 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Aug 1, 2012 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Jul 6, 2012 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jul 6, 2012 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jul 6, 2012 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jun 29, 2012 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 28, 2012 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 28, 2012 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 25, 2012 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 25, 2012 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 25, 2012 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 25, 2012 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 13, 2011 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 10, 2011 | NWAP | NEW APPLICATION ENTERED | — |